Connect with us
Ozempic, manufactured by Novo Nordisk, gains EMA approval for chronic kidney disease, reducing disease progression by 24%, per the Flow trial. With 40% of type 2...
Bayer expands its Barcelona innovation hub with a new R&D area for health and agriculture, integrating 82 professionals to advance clinical trials and medicine safety. The...
Quirónsalud and Roche Farma España have signed a partnership to advance healthcare innovation and clinical research, focusing on oncology, neurosciences, and ophthalmology. The agreement includes precision...
Croma Gio.Batta Iberia, post-merger with Cogesa, anticipates double-digit growth fueled by a 15% revenue rise to over €30M. The group, now a leading provider of healthcare...
Eli Lilly will invest $3 billion to expand its Kenosha, Wisconsin, facility, acquired for $100 million in April. The site will manufacture injectable diabetes and obesity...
Sanofi will invest €1 billion in a new insulin factory in Beijing, its largest investment in China, citing demand from 140 million diabetic adults. This fourth...
Mason Capital, owning 2.1% of Grifols' Class A shares, seeks Tomás Dagá's resignation, citing governance concerns and shareholder value loss. The fund demands transparency on Dagá’s...
Leitat projects €48M in 2023 revenue, with 20% from R&D. Its health division, founded in 2009, specializes in therapies and health predictors, focusing on personalized medicine...
Spanish pharmaceutical stocks dropped 10% in November, led by Rovi's 17.5% plunge amid profit and turnover declines. Grifols also fell 16%, impacted by OPA cancellation and...
Gotham City raises doubts about Grifols following Brookfield's withdrawal from a takeover bid, claiming the firm lacked access to crucial data. Grifols shares dropped 14%, compounding...